BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35582231)

  • 1. Aberrant DNA repair as a potential contributor for the clonal evolution in subsets of anaplastic thyroid carcinomas arising through dedifferentiation: implications for future therapeutic algorithms?
    Juhlin CC
    Cancer Drug Resist; 2020; 3(4):992-1000. PubMed ID: 35582231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-genome sequencing of synchronous thyroid carcinomas identifies aberrant DNA repair in thyroid cancer dedifferentiation.
    Paulsson JO; Backman S; Wang N; Stenman A; Crona J; Thutkawkorapin J; Ghaderi M; Tham E; Stålberg P; Zedenius J; Juhlin CC
    J Pathol; 2020 Feb; 250(2):183-194. PubMed ID: 31621921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clonal evolution analysis of paired anaplastic and well-differentiated thyroid carcinomas reveals shared common ancestor.
    Dong W; Nicolson NG; Choi J; Barbieri AL; Kunstman JW; Abou Azar S; Knight J; Bilguvar K; Mane SM; Lifton RP; Korah R; Carling T
    Genes Chromosomes Cancer; 2018 Dec; 57(12):645-652. PubMed ID: 30136351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.
    Nikitski AV; Rominski SL; Condello V; Kaya C; Wankhede M; Panebianco F; Yang H; Altschuler DL; Nikiforov YE
    Thyroid; 2019 Oct; 29(10):1425-1437. PubMed ID: 31298630
    [No Abstract]   [Full Text] [Related]  

  • 5. Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing.
    Duan H; Li Y; Hu P; Gao J; Ying J; Xu W; Zhao D; Wang Z; Ye J; Lizaso A; He Y; Wu H; Liang Z
    Histopathology; 2019 Dec; 75(6):890-899. PubMed ID: 31230400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Search for new genetic biomarkers in poorly differentiated and anaplastic thyroid carcinomas using next generation sequencing.
    Sykorova V; Dvorakova S; Vcelak J; Vaclavikova E; Halkova T; Kodetova D; Lastuvka P; Betka J; Vlcek P; Reboun M; Katra R; Bendlova B
    Anticancer Res; 2015 Apr; 35(4):2029-36. PubMed ID: 25862857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
    Landa I; Ibrahimpasic T; Boucai L; Sinha R; Knauf JA; Shah RH; Dogan S; Ricarte-Filho JC; Krishnamoorthy GP; Xu B; Schultz N; Berger MF; Sander C; Taylor BS; Ghossein R; Ganly I; Fagin JA
    J Clin Invest; 2016 Mar; 126(3):1052-66. PubMed ID: 26878173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas.
    Soares P; Lima J; Preto A; Castro P; Vinagre J; Celestino R; Couto JP; Prazeres H; Eloy C; Máximo V; Sobrinho-Simões M
    Curr Genomics; 2011 Dec; 12(8):609-17. PubMed ID: 22654560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic Landscape of poorly Differentiated and Anaplastic Thyroid Carcinoma.
    Xu B; Ghossein R
    Endocr Pathol; 2016 Sep; 27(3):205-12. PubMed ID: 27372303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations.
    Russo MA; Kang KS; Di Cristofano A
    Thyroid; 2013 Oct; 23(10):1284-93. PubMed ID: 23509868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microsatellite Instability Occurs in a Subset of Follicular Thyroid Cancers.
    Genutis LK; Tomsic J; Bundschuh RA; Brock PL; Williams MD; Roychowdhury S; Reeser JW; Frankel WL; Alsomali M; Routbort MJ; Broaddus RR; Wakely PE; Phay JE; Walker CJ; de la Chapelle A
    Thyroid; 2019 Apr; 29(4):523-529. PubMed ID: 30747051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma.
    Wang HM; Huang YW; Huang JS; Wang CH; Kok VC; Hung CM; Chen HM; Tzen CY
    Ann Surg Oncol; 2007 Oct; 14(10):3011-8. PubMed ID: 17638058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 protein expression in synchronously occurring dedifferentiating stages of thyroid cancer in a patient with neurofibromas: A case report.
    Boutzios G; Papaoiconomou E; Pikoulis A; Nastos K; Pouloudi D; Pikouli A; Koukoulioti E; Lazaris A; Pikoulis E
    Mol Clin Oncol; 2021 Oct; 15(4):200. PubMed ID: 34462656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell cycle deregulation and TP53 and RAS mutations are major events in poorly differentiated and undifferentiated thyroid carcinomas.
    Pita JM; Figueiredo IF; Moura MM; Leite V; Cavaco BM
    J Clin Endocrinol Metab; 2014 Mar; 99(3):E497-507. PubMed ID: 24423316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dedifferentiation patterns in DTC: is PDTC an intermediate state between DTC and ATC?
    Wen D; Hu JQ; Wei WJ; Ma B; Lu ZW; Wang YL; Wang Y; Ji QH
    Int J Clin Exp Pathol; 2019; 12(1):267-274. PubMed ID: 31933742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of E-Cadherin and β-Catenin Immunoreactivity for Determining Undifferentiated Cells in Anaplastic Thyroid Carcinoma.
    Kanematsu R; Hirokawa M; Tanaka A; Suzuki A; Higuchi M; Kuma S; Hayashi T; Miyauchi A
    Pathobiology; 2021; 88(5):351-358. PubMed ID: 34237735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.
    Dierks C; Seufert J; Aumann K; Ruf J; Klein C; Kiefer S; Rassner M; Boerries M; Zielke A; la Rosee P; Meyer PT; Kroiss M; Weißenberger C; Schumacher T; Metzger P; Weiss H; Smaxwil C; Laubner K; Duyster J; von Bubnoff N; Miething C; Thomusch O
    Thyroid; 2021 Jul; 31(7):1076-1085. PubMed ID: 33509020
    [No Abstract]   [Full Text] [Related]  

  • 19. MMP1 acts as a potential regulator of tumor progression and dedifferentiation in papillary thyroid cancer.
    Zhou J; Xu M; Tan J; Zhou L; Dong F; Huang T
    Front Oncol; 2022; 12():1030590. PubMed ID: 36479070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas.
    Nikiforov YE
    Endocr Pathol; 2004; 15(4):319-27. PubMed ID: 15681856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.